Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech firm based in Chengdu, has announced that it has received approval from the National Medical Products Administration (NMPA) to commence a clinical study for its drug candidate HP568. This new drug is intended for the treatment of estrogen receptor (ER) positive, human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced breast cancer.
HP568 is an innovative ERα-targeted PROteolysis TArgeting Chimera (PROTAC) drug, which is designed to consist of a target protein ligand, an E3 ligase ligand, and a linker between the two ligands. Preclinical study results have demonstrated that HP568 exhibits its anti-proliferative activity by specifically catalyzing the proteasome-dependent rapid degradation of ER α. The drug has shown strong degradation activity against both wild-type ER α protein and clinically common ER α mutant proteins. In vivo mouse model studies have indicated that HP568 can dose-dependently inhibit the growth of transplanted tumors, and it has shown good safety profiles. Notably, there is no similar product approved globally, making HP568 a potentially groundbreaking therapy in the field.- Flcube.com
